146 related articles for article (PubMed ID: 36198483)
1. Preferential
Giger OT; Ten Hoopen R; Shorthouse D; Abdullahi S; Bulusu VR; Jadhav S; Maher ER; Casey RT
J Clin Pathol; 2023 Dec; 77(1):34-39. PubMed ID: 36198483
[TBL] [Abstract][Full Text] [Related]
2. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Ricci R; Martini M; Ravegnini G; Cenci T; Milione M; Lanza P; Pierconti F; Santini D; Angelini S; Biondi A; Rosa F; Alfieri S; Clemente G; Persiani R; Cassano A; Pantaleo MA; Larocca LM
Clin Epigenetics; 2019 Jan; 11(1):2. PubMed ID: 30616628
[TBL] [Abstract][Full Text] [Related]
3. Recurrent epimutation of SDHC in gastrointestinal stromal tumors.
Killian JK; Miettinen M; Walker RL; Wang Y; Zhu YJ; Waterfall JJ; Noyes N; Retnakumar P; Yang Z; Smith WI; Killian MS; Lau CC; Pineda M; Walling J; Stevenson H; Smith C; Wang Z; Lasota J; Kim SY; Boikos SA; Helman LJ; Meltzer PS
Sci Transl Med; 2014 Dec; 6(268):268ra177. PubMed ID: 25540324
[TBL] [Abstract][Full Text] [Related]
4. SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice.
Casey RT; Ten Hoopen R; Ochoa E; Challis BG; Whitworth J; Smith PS; Martin JE; Clark GR; Rodger F; Maranian M; Allinson K; Madhu B; Roberts T; Campos L; Anstee J; Park SM; Marker A; Watts C; Bulusu VR; Giger OT; Maher ER
Sci Rep; 2019 Jul; 9(1):10244. PubMed ID: 31308404
[TBL] [Abstract][Full Text] [Related]
5. SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.
Urbini M; Astolfi A; Indio V; Heinrich MC; Corless CL; Nannini M; Ravegnini G; Biasco G; Pantaleo MA
BMC Med Genet; 2015 Sep; 16():87. PubMed ID: 26415883
[TBL] [Abstract][Full Text] [Related]
6. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
7.
Schipani A; Nannini M; Astolfi A; Pantaleo MA
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980917
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
9. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L
Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673
[TBL] [Abstract][Full Text] [Related]
10. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
12. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations of SDH genes in patients with sporadic succinate dehydrogenase-deficient gastrointestinal stromal tumors.
Shi SS; Wang YF; Bao W; Ye SB; Wu N; Wang X; Xia QY; Li R; Shen Q; Zhou XJ
Pathol Int; 2019 Jun; 69(6):350-359. PubMed ID: 31273876
[TBL] [Abstract][Full Text] [Related]
14. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
[TBL] [Abstract][Full Text] [Related]
15. MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area.
Yousuf A; Bhat MY; Pandith AA; Afroze D; Khan NP; Alam K; Shah P; Shah MA; Mudassar S
Cell Oncol (Dordr); 2014 Aug; 37(4):245-52. PubMed ID: 25008999
[TBL] [Abstract][Full Text] [Related]
16. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Chen WJ; Zhang X; Han H; Lv JN; Kang EM; Zhang YL; Liu WP; He XS; Wang J; Wang GH; Yu YB; Zhang W
Cell Death Dis; 2020 Aug; 11(8):668. PubMed ID: 32820151
[TBL] [Abstract][Full Text] [Related]
17. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.
Killian JK; Kim SY; Miettinen M; Smith C; Merino M; Tsokos M; Quezado M; Smith WI; Jahromi MS; Xekouki P; Szarek E; Walker RL; Lasota J; Raffeld M; Klotzle B; Wang Z; Jones L; Zhu Y; Wang Y; Waterfall JJ; O'Sullivan MJ; Bibikova M; Pacak K; Stratakis C; Janeway KA; Schiffman JD; Fan JB; Helman L; Meltzer PS
Cancer Discov; 2013 Jun; 3(6):648-57. PubMed ID: 23550148
[TBL] [Abstract][Full Text] [Related]
18. Impact of catechol-O-methyltransferase gene variants on methylation status of P16 and MGMT genes and their downregulation in colorectal cancer.
Wani HA; Majid S; Bhat AA; Amin S; Farooq R; Bhat SA; Naikoo NA; Beigh MA; Kadla SA
Eur J Cancer Prev; 2019 Mar; 28(2):68-75. PubMed ID: 30379684
[TBL] [Abstract][Full Text] [Related]
19. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
Flavahan WA; Drier Y; Johnstone SE; Hemming ML; Tarjan DR; Hegazi E; Shareef SJ; Javed NM; Raut CP; Eschle BK; Gokhale PC; Hornick JL; Sicinska ET; Demetri GD; Bernstein BE
Nature; 2019 Nov; 575(7781):229-233. PubMed ID: 31666694
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q; Berglund AE; Macaulay RJ; Etame AB
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
